Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

MBIO vs ARTV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARTV Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 3–3 Matrix Metrics)

ARTV Overall Winner 6-Pillar Tally: MBIO 2 – 2 ARTV (2 Tie) Matrix Metrics: MBIO 3 – 3 ARTV

As of Nov 17, 2026, Artiva Biotherapeutics, Inc. (ARTV) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas ARTV carries 48.5/100 (HOLD) at $3.90 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ARTV earns the overall head-to-head edge with a stronger Unified Composite Score (48.5/100 HOLD vs. MBIO 42.9/100 HOLD) and 1.73β · 116% Vol risk profile, whereas MBIO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile ARTV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MBIO vs ARTV
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-0.58% 1D
Market Cap $3.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.68β · 85% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.4 · SMA20: $0.40 · SMA50: $0.44
ARTV NASDAQ Head-to-Head Winner
Artiva Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.90
-1.52% 1D
Market Cap $198.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.73β · 116% Vol
Unified Composite Score
48.5 / 100 HOLD
Tech 50.0 Fund 60.0 Flow 64.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.3%), weak momentum, RSI 22
RSI-14: 22.2 · SMA20: $4.68 · SMA50: $6.51

6-Pillar Scorecard Institutional Category Breakdown (MBIO 2 – 2 ARTV)

Columns: Metric · MBIO · ARTV
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale MBIO
Revenue Growth (YoY) +0.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $3.2M $198.2M
3. Profitability & Quality MBIO
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -43.1% -43.6%
4. Balance Sheet & Cash Flow ARTV
Cash Generation (TTM) N/A -$87M
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.87 Book/Sh · -43.1% ROE $52M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ARTV
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 53.6% (<1st %ile)
Put/Call OI Skew N/A 0.37x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MBIO (3) vs ARTV (3)
Institutional Metric MBIO ARTV Criterion Row Edge
Market Capitalization
Scale
$3.2M $198.2M Larger Scale ARTV
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -100.0% Higher Growth MBIO
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-43.1% -43.6% Higher ROE MBIO
52-Week Range Position
Momentum
4% ($0–$1) 8% ($3–$15) Stronger Trend ARTV
Beta / 30D Volatility
Risk Regime
0.68β · 85% Vol 1.73β · 116% Vol Lower Realized Risk MBIO
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 48.5 / 100 (HOLD) Higher Composite ARTV
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.87 Book/Sh · -43.1% ROE) -$87M ($52M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBIO +38.99 pp
MBIO: +5.2% · ARTV: -33.79%
3M Horizon MBIO +35.03 pp
MBIO: -31.64% · ARTV: -66.67%
6M Horizon MBIO +15.52 pp
MBIO: -38.87% · ARTV: -54.39%
1Y Horizon ARTV +87.84 pp
MBIO: -67.84% · ARTV: +20.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs ARTV. Trailing 12-month operating profitability (MBIO 0.0% vs ARTV 0.0%) and valuation multiples (MBIO N/M vs ARTV N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MBIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-43.1% · N/M
ARTV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-43.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARTV BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 53.6%
IV Percentile <1st %ile
Put/Call OI Skew 0.37x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ARTV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ARTV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $198.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MBIO vs ARTV Key Questions & Quantitative Answers

As of Nov 17, 2026, Artiva Biotherapeutics, Inc. (ARTV) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas ARTV carries 48.5/100 (HOLD) at $3.90 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ARTV earns the overall head-to-head edge with a stronger Unified Composite Score (48.5/100 HOLD vs. MBIO 42.9/100 HOLD) and 1.73β · 116% Vol risk profile, whereas MBIO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile ARTV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MBIO leads the Growth & Scale pillar: MBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ARTV at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MBIO generates N/A in USD-normalized revenue versus N/A for ARTV. In operating R&D and SG&A reinvestment, MBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARTV.

MBIO and ARTV trade at balanced relative valuation multiples. MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ARTV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBIO (-43.1% ROE) versus ARTV (-43.6% ROE) capital efficiency.

In options market volatility and institutional positioning, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 85% Vol realized risk). By comparison, ARTV carries 53.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.37x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.73β · 116% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.